Impact of genetic polymorphisms on the efficacy of HMG-CoA reductase inhibitors

American Journal of Cardiovascular Drugs

Volumn 8, Issue 3, 2008, Pages 161-170

  Hutz, Mara H ^a   Fiegenbaum, Marilu ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Methodist University Center   (Brazil)

Author keywords

Cardiovascular disorders, prevention; Genetic polymorphism; HMG CoA reductase inhibitors, therapeutic use; Hyperlipidaemia, treatment

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PRAVASTATIN; PROTEIN SCAP; REGULATOR PROTEIN; ROSUVASTATIN; SIMVASTATIN; SQUALENE SYNTHASE; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ALLELE; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MUSCLE LEVEL; DRUG TRANSPORT; DRUG WITHDRAWAL; DYSPEPSIA; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL SYMPTOM; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIVER DISEASE; LIVER TOXICITY; MONOTHERAPY; MUSCLE DISEASE; MUSCLE INJURY; MYALGIA; MYOPATHY; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 44949222478     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200808030-00003     Document Type: Review

References (97)

1. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000; 355: 688-700
2. Mansur AP, Souza MF, Timerman A, et al. Trends in the risk of death from cardiovascular, cerebrovascular and ischemic diseases in thirteen states of Brazil from 1980 to 1998. Arq Bras Cardiol 2006; 87: 641-8
3. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-96
4. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30
5. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1-34
6. Gotto AM. Statin therapy: where are we? Where do we go next? Am J Cardiol 2001; 87: 13B-8B
7. Waters, DD. Are we aggressive enough in lowering cholesterol? Am J Cardiol 2001; 88: 10F-5F
8. Kreisberg RA, Oberman A. Lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab 2002; 87: 423-37
9. Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2003; 21: 199-215
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9
11. Miettinen TA, Gylling H, Strandberg T, et al. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian Simvastatin Survival Study. Finnish 4S Investigators. BMJ 1998; 316: 1127-30
12. Garcia Ruiz FJ, Marin Ibanez A, Perez-Jimenez F, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. Pharmacogenomics 2004; 22: 1-12
13. Kajinami K, Akao H, Polisecki E, et al. Pharmacogenomics of statin responsiveness. Am J Cardiol 2005; 96: 65K-70K
14. Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006; 6: 360-74
15. Schmitz G, Schmitz-Madry A, Ugocsai P. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr Opin Lipidol 2007; 18: 164-73
16. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, et al. Effect of apolipoprotein and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995; 113: 157-66
17. Sanllehy C, Casals E, Rodriguez-Villar C, et al. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism 1998; 47: 560-5
18. Ballantyne CM, Herd JA, Stein EA, et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000; 36: 1572-8
19. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001; 158: 183-93
20. Pena R, Lahoz C, Mostaza JM, et al. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an out patient stetting. J Intern Med 2002; 251: 518-25
21. Ojala JP, Helve E, Ehnholm C, et al. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J Intern Med 1991; 230: 397-405
22. Fiegenbaum M, da Silveira FR, Van der Sand CR, et al. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin Chim Acta 2005; 362: 182-8
23. Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291: 2821-7
24. Kajinami K, Brousseau ME, Lamon-Fava S, et al. Gender-specific effects of estrogen receptor α gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism. Atherosclerosis 2005; 178: 331-8
25. Thompson JF, Man M, Johnson K, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005; 5: 352-8
26. Sorkin SC, Forestiero FJ, Hirata MH, et al. APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals. Clin Chem Lab Med 2005; 43: 1339-45
27. Guzman EC, Hirata MH, Quintao EC, et al. Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease. Clin Chem Lab Med 2000; 38 (8): 731-6
28. Ye P, Shang Y, Ding X. The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia. Chin Med Sci J 2003; 18: 9-13
29. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338: 86-93
30. De Grooth GJ, Zerba KE, Huang SP, et al. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the Cholesterol And Recurrent Events study: no interaction with response to pravastatin therapy and no effects no cardiovascular outcome. J Am Coll Cardiol 2004; 43: 854-7
31. Freeman DJ, Samani NJ, Wilson V, et al. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur Heart J 2003; 24: 1833-42
32. Van Venrooij FV, Stolk RP, Banga JD, et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type diabetes. Diabetes Care 2003; 26: 1216-23
33. Carlquist JF, Muhlestein JB, Horne BD, et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J 2003; 146: 1007-14
34. Klerkx AHEM, de Grooth GJ, Zwinderman AH, et al. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004; 34: 21-8
35. Winkelmann BR, Hoffmann MM, Nauck M, et al. Haplotypes of the cholesteryl ester transfer protein predict lipid-modifying response to statin therapy. Pharmacogenomics J 2003; 3: 284-96
36. Bercovich D, Friedlander Y, Korem S, et al. The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis 2006; 185: 97-107
37. Fan YM, Laaksonen R, Janatuinen T, et al. Effects of pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating protein polymorphism in healthy young men. Clin Genet 2001; 60: 319-21
38. Salek L, Lutucuta S, Ballantyne CM, et al. Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med 2002; 80: 737-44
39. Fiegenbaum M, Silveira FR, Van der Sand CR, et al. Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J 2005; 5: 359-64
40. Zambon A, Deeb SS, Brown BG, et al. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 2001; 103: 792-8
41. Cenarro A, Artieda M, Gonzalvo C, et al. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response. Am Heart J 2005; 150: 1154-62
42. Lahoz C, Pena R, Mostaza JM, et al. The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis 2005; 182: 129-34
43. Berk-Planken II, Hoogerbrugge N, Stolk RP, et al. Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant. Diabetes Care 2003; 26: 427-32
44. Garcia-Otin AL, Civeira F, Aristegui R, et al. Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment. Eur J Clin Invest 2002; 32: 421-8
45. Sing K, Ballantyne CM, Ferlic L, et al. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis 1999; 144: 435-42
46. Jukema JW, van Boven AJ, Groenemeijer B, et al. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis: REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. Circulation 1996; 94: 1913-8
47. Goodarzi MO, Taylor KD, Scheuner MT, et al. Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts. Pharmacogenomics J 2007; 7: 66-73
48. Kajinami K, Brousseau ME, Ordovas JM, et al. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 2004; 175: 287-93
49. Kajinami K, Brousseau ME, Nartsupha C, et al. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J Lipid Res 2004; 45: 653-6
50. Garcia-Garcia AB, Gonzalez C, Real JT, et al. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia. Pharmacogenet Genomics 2005; 15: 211-8
51. Ledmyr H, McMahon AD, Ehrenborg E, et al. The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease. Circulation 2004; 109 (19): 2279-84
52. Lutucuta S, Ballantyne CM, Elghannam H, et al. Novel polymorphisms in promoter region of ATP binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res 2001; 88: 969-73
53. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-30
54. Hoffmann MM, Winkelmann BR, Wieland H, et al. The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs. Pharmacogenomics 2001; 2: 1-10
55. Schmitz G, Langmann T. Pharmacogenomics of cholesterol-lowering therapy. Vascul Pharmacol 2006; 44: 75-89
56. Hannuksela ML, Liinamaa MJ, Kesaniemi YA, et al. Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis 1994; 110: 35-44
57. Kuivenhoven JA, de Knijff P, Boer JM, et al. Heterogeneity at the CETP gene locus: influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997; 17: 560-8
58. Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 2003; 44: 1080-93
59. Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005; 111: 278-87
60. Eberle D, Hegarty B, Bossard P, et al. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004; 86: 839-48
61. Edwards PA, Tabor D, Kast HR, et al. Regulation of gene expression by SREBP and SCAP. Biochim Biophys Acta 2000; 1529: 103-13
62. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31
63. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl-coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001; 57: 357-64
64. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-94
65. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91
66. Kajinami K, Brousseau ME, Ordovas JM, et al. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004; 93: 104-7
67. Kivisto K, Niemi M, Schaefeller E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004; 14: 523-5
68. Fiegenbaum M, da Silveira FR, Van der Sand CR, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005; 78: 551-8
69. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468-85
70. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2001; 97: 3473-8
71. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-74
72. Kimchi-Sarfaty C, Oh JM, Kim I-W, et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525-8
73. Kajinami K, Brousseau ME, Ordovas JM, et al. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 2004; 93: 1046-50
74. Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75: 415-21
75. Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73: 554-65
76. Takane H, Miyata M, Burioka N, et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 2006; 51: 822-6
77. Pasanen MK, Neuvonen M, Neuvonen P, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16: 873-9
78. Tomlinson B, Chan P, Lan W. How well tolerated are lipid-lowering drugs? Drugs Aging 2001; 18: 665-83
79. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001; 175: 486-9
80. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics 2005; 15: 415-21
81. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99: 95-112
82. Bray PF, Cannon CP, Goldschmidt-Clermont P, et al. The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001; 88: 347-52
83. Marian AJ, Safavi F, Ferlic L, et al. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol 2000; 35: 89-95
84. Walter DH, Schachinger V, Elsner M, et al. Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the PlA2 allele of the platelet glycoprotein IIIa gene. Eur Heart J 2001; 22: 587-95
85. Boekholdt SM, Agema WR, Peters RJ, et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003; 107: 2416-21
86. Holloway JW, Yang IA, Ye S. Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet Genomics 2005; 15: 15-21
87. Elghannam H, Tavackoli S, Ferlic L, et al. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med 2000; 78: 562-8
88. Basso F, Lowe GD, Rumley A, et al. Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland Coronary Prevention Study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002; 22: 599-604
89. Puccetti L, Pasqui AL, Pastorelli M, et al. 3′UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects. Atherosclerosis 2005; 183: 322-8
90. Puccetti L, Pasqui AL, Bruni F, et al. Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment. Int J Cardiol 2007; 119: 41-7
91. Maintland-van der Zee AH, Boerwinkle E, Arnett DK, et al. Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Am Heart J 2007; 153: 54-8
92. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trial for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004; 44: 720-32
93. Dean BB, Borenstein JE, Henning JM, et al. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? Am Heart J 2004; 147: 966-76
94. Pearson T, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP). Arch Intern Med 2000; 160: 459-67
95. Maitland-van der Zee AH, Stricker BH, Klungel OH, et al. Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotype. Pharmacogenetics 2003; 13: 219-23
96. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
97. Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005; 31: 572-80